The director will test whether scale preserves care integrity
The Board seeks an Audit Committee contributor for a healthcare enterprise operating across multiple facilities, specialties and service channels. The central governance question is whether financial reporting, capital investment and operating assurance reflect the same reality experienced in care delivery—without fragmenting accountability for quality, access and patient experience.
Strategy at Board altitude
Expansion proposals should identify population need, service model, clinical capability, leadership, capital, referral and payer dynamics, technology, quality assurance and downside. The director will distinguish buildings or capacity from a functioning care system. A new facility or service is not ready because construction or equipment is complete; staffing, protocols, escalation, supply, data and continuity must also be credible.
Acquisitions and partnerships require scrutiny of clinical governance, credentialing, data, culture, liabilities, quality history, talent retention and integration cost. The Board should know which standards are non-negotiable and how quickly acquired operations must converge.
Capital follow-through
Major investments will retain their original assumptions for demand, clinician availability, commissioning, ramp-up, utilisation, payer mix, quality and cash. Post-investment review should distinguish construction completion from clinical and economic readiness. Where reality departs from the approved case, the director will ask whether management is adapting the operating model, changing the capital sequence or merely extending the time allowed for the original promise.
Accountability beneath the numbers
The Audit Committee will test whether leaders of clinical governance, operations, nursing, finance, digital, quality and major businesses own the evidence entering Board reports. Facility and specialty accountability is material: revenue, cost, provision and asset judgements weaken when local clinical and operating authority is unclear.
Management representations should be examined against outcome, multidisciplinary collaboration, resource judgement and response to adverse events—not solely growth or occupancy. The director will examine whether clinical and control leaders have direct access and sufficient independence from commercial pressure.
Reward architecture
Metrics should reconcile financial performance with quality, safety, patient experience, workforce stability, access and capital utilisation. Volume, procedure or occupancy incentives require careful review for inappropriate demand, coding, provisioning or discharge pressure. The committee will ask whether remuneration pressure affects estimates, escalation or the completeness of operating evidence.
Technology and data in strategy
Digital pathways, analytics and AI must be examined for clinical authority, consent, data quality, human review, bias, cyber resilience and remedy. Technology should improve continuity and decision quality rather than create fragmented channels or unreviewed clinical reliance.
The first Board review
The appointee will select one material growth initiative and perform a readiness review across clinical leadership, workforce, quality, systems, capital and patient journey. The output should identify Board decision gates and the evidence needed before the next commitment.
Candidate standing
Applicants may be healthcare CFOs or CEOs, hospital/network leaders, audit partners, clinicians with enterprise governance experience, payor executives, or senior leaders in healthcare quality and assurance. They must understand the line between oversight and clinical management. Audit Committee experience is preferred. Independence, DIN, databank compliance and capacity for site visits and audit/quality sessions are essential.